Washington D.C : A new study has offered hope for Type 2 diabetic men, who are experiencing problems in their sex lives.
In a recent placebo-controlled study, long acting testosterone undecanoate (an ester of testosterone) improved erectile function, intercourse satisfaction, and sexual desire scores in type 2 diabetic men with severe hypogonadism, a condition in which the body doesn’t produce enough testosterone.
Only sexual desire improved significantly with testosterone replacement therapy in those with mild hypogonadism.
“The study’s results also suggest that trials of testosterone therapy should be for a minimum of 6 months and not shorter periods as suggested by some guidelines,” said lead author Dr. Geoffrey Hackett.
The study appears in the journal BJU International.
Latest posts by supriya kashyap (see all)
- Adenoiditis – GOI Standard Treatment Guidelines - October 25, 2018
- Chronic Laryngitis – GOI Standard Treatment Guidelines - October 23, 2018
- Wilms tumour- GOI Standard Treatment Guidelines - October 22, 2018